Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Long-Term Follow Up Study for AMD3100 Patients

This study has been completed.
Sponsor:
Collaborator:
AnorMED
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00476294
First received: May 17, 2007
Last updated: July 10, 2012
Last verified: July 2012

May 17, 2007
July 10, 2012
October 2006
July 2012   (final data collection date for primary outcome measure)
  • Progression-free Survival at 5 Years [ Time Frame: 5 Years ] [ Designated as safety issue: No ]
    Progression-free survival defined as number of participants without disease progression at five years following the first dose of study treatment (placebo or plerixafor [AMD3100]).
  • Overall survival at 5 Years [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Overall survival defined as number of participants alive after a period of five years following the first dose of study treatment (placebo or plerixafor [AMD3100]).
Not Provided
Complete list of historical versions of study NCT00476294 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Long-Term Follow Up Study for AMD3100 Patients
Long-Term Observational Follow-Up Study of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240 MCG/KG) Plus G-CSF (10 MCG/KG) Versus G-CSF (10 MCG/KG) Plus Placebo to Mobilize and Collect >/= 6 x 10^6 CD34+ Cells/KG in Multiple Myeloma Patients for Autologous Transplantation

Objectives:

The objective of this long-term observational study is to assess progression-free survival and overall survival for a period of five years following the first dose of study treatment (placebo or plerixafor [AMD3100]) in protocol AMD3100-3102. Patients that received at least 1 dose of study treatment (placebo or plerixafor) in the multicenter, randomized, double-blind, placebo-controlled AMD3100-3102 study, which was designed to evaluate plerixafor plus granulocyte colony stimulating factor (G-CSF) versus placebo plus G-CSF to mobilize hematopoietic stem cells for autologous transplantation of Multiple Myeloma (MM) patients are eligible.

Informed Consent Process:

Your study doctor or staff will either meet with you in person or contact you by phone to review the study information. You will be given a copy of this consent form to review and ask questions.

If you agree to take part in this study, you should sign this consent form on the date that you agree to be in the study. If you agree to take part during a phone call with a member of the study team, you should sign and date the form right away, on the date of the phone call, and mail the form to the study doctor or staff. Please keep a copy for your own reference.

5-Year Follow-Up: You will be contacted by phone or in person at a visit, every 6 months for 5 years from the time of your first study drug/placebo dose in the 2004-0982 study. A placebo is a substance that looks like the study drug but has no active ingredients.

If you received a transplant in the 2004-0982 study, your first contact in this study will either be about 18 months from the time you began the 2004-0982 study, or at the time you sign this consent form.

If you did not receive a transplant, your first contact in this study will be at the time you sign this consent form.

At your first visit or call, you will be asked about the status of the disease, any changes in the multiple myeloma that may have occurred since the 2004-0982 study, and any additional treatments you may have received during that time.

At every visit or call after that, you will be asked about the status of the multiple myeloma, any changes in the disease, and any treatments you have received since the last visit or call. These questionnaires will take about 10 minutes each time.

Your doctor or the study staff also may contact your local doctor in order to collect information from your medical records or for information about your medical history and disease status.

Length of Study Participation:

You will be off study after your last study phone call or visit (about 5 years after your first study drug/placebo dose in the 2004-0982 study).

This is an investigational study. Up to 300 patients will participate in this multi-center study. Up to 12 will be enrolled at MD Anderson.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Patients who were randomized in a double-blind study and received a stem cell transplant after treatment with AMD3100 and G-CSF OR treatment with Placebo and G-CSF.

Myeloma
Other: Telephone Questionnaire
Follow-Up Telephone Calls Every 6 Months for 5 Years.
Other Name: Survey
  • Group 1: G + Placebo
    G-CSF plus Placebo Arm (G + Placebo)
    Intervention: Other: Telephone Questionnaire
  • Group 2: G + AMD3100
    G-CSF plus AMD3100 Arm (G + AMD3100)
    Intervention: Other: Telephone Questionnaire
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
7
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 1) All patients who received the study drug (placebo or plerixafor) on protocol AMD3100-3102 (2004-0982)

Exclusion Criteria: None

Both
18 Years to 78 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00476294
2006-0665
Yes
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AnorMED
Principal Investigator: Chitra M. Hosing, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP